Figure 6.

In a Setting of Recurrent Tumor, Prior Immunity to NDV Potentiates Immune Infiltration in Distant Tumors

(A) Treatment scheme in the bilateral flank tumor model. Primary tumors were established by implantation of 1 × 10⁵ B16-F10 cells in the right flank. Recurrent tumors were modeled by implantation of 4 × 10⁵ B16-F10 cells in the bilateral flanks. (B) Absolute number of tumor-infiltrating CD45⁺, CD11b⁺, NK, and CD3⁺ cells in distant tumors, calculated from flow cytometry. (C) Absolute number of tumor-infiltrating CD8⁺, T_con, and T_reg cells per gram of tumor in distant tumors, calculated from flow cytometry. (D) Relative percentages of tumor-infiltrating T_regs out of CD4⁺ cells. Data represent one of two independent experiments with n = 5, n = 5, n = 5, and n = 6, as above. Mean ± SEM is shown. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. R, right; L, left; BL, bilateral.